Adherence, tolerability, and outcome after 36 months of isoniazid-preventive therapy in 2 rural clinics of Swaziland: A prospective observational feasibility study. by Mueller, Y. et al.
Observational Study Medicine®
OPENAdherence, tolerability, and outcome after
36 months of isoniazid-preventive therapy
in 2 rural clinics of Swaziland
A prospective observational feasibility study
Yolanda Mueller, MD, MIHa,
∗
, Qhubekani Mpala, MScb, Bernhard Kerschberger, MD, MPHb,
Barbara Rusch, MIHb, Gugu Mchunu, MPHc, Sikhathele Mazibuko, MDd, Maryline Bonnet, MD, PhDa,e
Abstract
Although efﬁcacy of 36 months isoniazid preventive therapy (IPT) among HIV-positive individuals has been proven in trial settings,
outcome, tolerance, and adherence have rarely been evaluated in real-life settings.
This is a prospective observational cohort study conducted in 2 primary care rural clinics in Swaziland.
After negative tuberculosis symptom screening, patients either with the positive tuberculin skin test (TST) or after tuberculosis
treatment were initiated on IPT for 144 weeks. In addition to routine clinic visits, adherence was assessed every semester.
Of 288 eligible patients, 2 patients never started IPT (1 refusal, 1 contraindication), and 253 (87.8%), 234 (81.3%), and 228 (79.2%)
were still on IPT after 48, 96, and 144 weeks, respectively (chi2P= .01). Of 41 patients who interrupted IPT before 144 weeks, 21
defaulted (of which 17 also defaulted HIV care); 16 stopped because of adverse drug reactions; 2 were discontinued by clinicians’
mistake and 1 because of TB symptoms. Five patients (1.7%) died of causes not related to IPT, 5 (1.7%) developed TB of which 2
were isoniazid-resistant, and 9 (3.1%) were transferred to another clinic. As an indicator of adherence, isoniazid could be detected in
the urine during 86.3% (302/350) and 73.6% (248/337) of patient visits in the 2 clinics, respectively (chi2 P< .001).
The routine implementation of IPT 36months was feasible and good patient outcomeswere achieved, with low TB incidence, good
tolerance, and sustained adherence.
Abbreviations: ADR= adverse drug reaction, ART= antiretroviral therapy, HIV= human immunodeﬁciency virus, INH= isoniazid,
IPT = isoniazid preventive therapy, IQR = interquartile range, PLHIV = people living with HIV, PY = person-years, TB = tuberculosis,
TST = tuberculin skin test, WHO = World Health Organization.
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In settings with high tuberculosis (TB) burden, isoniazid (INH)
Preventive Therapy (IPT) is recommended for prevention of
active tuberculosis in people living with HIV (PLHIV),
particularly in individuals who are tuberculin skin test (TST)-
positive.[1–3] In addition to antiretroviral therapy (ART), IPT
reduces the incidence of active TB[4] and was initiallyEditor: Wenyu Lin.
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1recommended for 6 months. However, effectiveness of IPT
has been shown to diminish 6 to 18 months after completion of
such a regimen,[5–7] suggesting that IPT should be provided for
longer. Indeed, a trial conducted in Botswana showed that TB
incidence among TST-positive PLHIV was reduced by a further
43% if IPT was given for 36 months as compared to 6 months,[8]
although the reduction was not signiﬁcant in PLHIV with
negative or unknown TST results.
Despite these results, uptake of 36 months’ IPT has been slow
inmany countries.[9–11] Main concerns about long-term IPTwere
risk of side-effects, patient adherence, development of active TB
while on IPT, and increased risk of INH-resistance. For example,
in South Africa, up to 28% of cases suffered from a grade 3 or 4
transaminase elevation, after a median of one-and-a-half year on
IPT and only 60% were retained on IPT at 3 years.[12] Besides,
although beneﬁts of IPT are greatest in TST-positive patients, the
introduction of widespread TST in resource-limited settings is
limited by operational constraints such as cold chain require-
ments and the extra-visit required for TST reading. Although
clinical trials have been essential to inform recommendations
about 36 months IPT, there have been no observational studies
documenting actual implementation. Conﬁrming results from
clinical trials in routine settings can help to convince decision-
makers about the added value of 36 months IPT.
Even though TB incidence has decreased in recent years,
Swaziland is still the country with the highest TB andHIV burden
reported in the world.[13] National TB control has focused on
Mueller et al. Medicine (2017) 96:35 Medicineearly detection and treatment of TB, in parallel with rapid scaling
up and integration of ART. Although IPT was recommended for
6 months, its implementation remained challenging in 2011, and
extending IPT duration to 36 months seemed unfeasible. There
was also the concern that adherence and outcomes under routine
conditions would be less favorable than those reported in clinical
trials. Therefore, the objective of this study was to assess the
feasibility of TST-based 36 months IPT strategy in HIV-infected
patients in programmatic conditions in 2 rural clinics of the
Shiselweni region in Swaziland, in order to inform policy-makers
in the country and in similar settings. This paper focuses on
adherence, tolerability, and outcomes after 48, 96, and 144
weeks of follow-up. The results of this study on initial patient
screening, implementation of tuberculin-skin test, and initiation
of IPT have been published previously.[14]2. Methods
This prospective observational cohort included PLHIV eligible
for IPT followed in 2 rural nurse-led primary care clinics in the
Shiselweni region, Kingdom of Swaziland (OLOS clinic in the
Hlatikulu zone and New Haven clinic in the Matsanjeni zone).
The study was undertaken in compliance with the Declaration of
Helsinki and was approved by the Social Welfare Scientiﬁc
Ethical Committee of Swaziland and the Médecins Sans
Frontières Ethical Review Board. Written informed consent
was obtained from all study participants.
Details of study setting and screening process can be found
elsewhere.[14] Brieﬂy, both clinics served an active ART cohort of
about 700 patients. Nurses were in charge of providing HIV-TB
care, which was fully integrated into general outpatient care.
Expert clients (PLHIV trained to provide patient support
education and counseling) assisted the nurses in managing
patient ﬁles and clinic registers, as well as adherence support.
Medical doctors visited the clinic once per week or every 2 weeks,
according to needs, to attend to complicated cases and offer
technical support.
The sample size was calculated to estimate the proportion of
positive TST.[14] The IPT study population, derived from the
proportion of positive TST, consisted of all at-least-16-years-old
PLHIV enrolled for HIV care at 1 of the 2 study clinics who were
eligible for 36months’ IPT based on either a positive TST (≥5mm
induration) or for secondary prophylaxis (after TB treatment[2]).
Exclusion criteria were kept to a minimum to be as close as
possible to the routine program conditions. According to
national recommendations for IPT provision, patients did not
receive IPT when they were on TB treatment, where TB was
suspected, or when INH was clinically contraindicated (e.g.
hepatitis and allergy). Informed consent was obtained before TST
screening.[14]
Intensiﬁed TB case-ﬁnding was implemented at every contact
between a PLHIV and the health facility, based on symptom
screening (cough, night sweats, fever, weight loss, or chest pain)
as per national recommendations.[15,16] Diagnosis of TB was
initially based on auramine-stained microscopical examination
and XpertMTB/RIF (Cepheid, Sun Valley) testing performed at
health-center level (secondary level), and later only on
XpertMTB/RIF as per national recommendations.[17] Samples
from smear- or Xpert-positive patients were sent to reference
laboratories at regional or national level for mycobacterial
culture and drug susceptibility testing.
Patients were seen after 1 month after starting IPT.
Subsequently, appointments followed the usual visit schedule2for ART or cotrimoxazole reﬁll, that is, every 1, 2, or 3 months
depending on patient, clinic, and drug stocks. Laboratory
monitoring followed the general recommendations for patients
under HIV care in Swaziland, namely 6-monthly CD4, and
quarterly liver function test. In 2012, viral-load testing was added
to routine monitoring as per the national VL algorithm. Expert
clients traced patients on HIV care by phone when clinical
appointments were missed by 3 days. A renewed attempt was
made by phone in cases where patients did not present at the
clinic over a period of 90 days. IPT outcome deﬁnitions were
adapted from the national standard deﬁnitions used to monitor 6
months’ IPT:[16] “default” was deﬁned as a patient who had
taken INH for at least 1 month, then interrupted for 60
consecutive days or more; “failure” was deﬁned as someone
developing active TB disease while on IPT; “treatment
discontinuation” was used for someone whose IPT had been
discontinued by a health care worker due to adverse effects or any
other reason; “transfer out” was used for someone who
transferred to another ART site or region to continue treatment;
“death”were those on IPTwhowere reported to have died of any
cause during the course of treatment; “completed IPT” was
deﬁned as a full course of 36 times 4 weeks (total 144 weeks) of
INH.
Pill count was systematically recorded at every patient contact.
In addition, for all patients on IPT for 36 months, an in-depth
evaluation was conducted twice yearly, consisting of a urine
sample and a short questionnaire. Adherence was assessed
through a combination of 4 parameters: pill count (i.e., the
number of INH tablets remaining in the INH blister when coming
for drug reﬁll, including reﬁll for antiretroviral or other
concomitant drug), the self-reported number of days of no
INH intake in the past 14 days, the Morisky scale, and isoniazid
testing in the urine. For this, isoniazid strip tests (BD TAXO INH
Test) were performed on urine samples following the manu-
facturer’s instructions. This test is mostly reliable for the presence
of isoniazid in the urine if the drug was taken in the last 24
hours.[18] The Morisky scale[19] combines 4 questions related to
different aspects of drug intake by patients on chronic treatment
(1. Do you ever forget to take your medicine? 2. Are you careless
at times about taking your medicine? 3. When you feel better do
you sometimes stop taking your medicine? 4. Sometimes if you
feel worse when you take the medicine, do you stop taking it?).
One point is attributed for every positive answer. Adherence is
judged high, intermediate, or low for scores of 0, 1 to 2, and 3 to
4, respectively.[19]
Data were collected by the clinic staff on regular patient ﬁles
during the routine follow-up visits, before extraction on study-
speciﬁc case report forms by a study nurse. Occurrence of adverse
drug reactions (ADR) was recorded in the patient ﬁle by the clinic
nurse. Adverse drug reactions were deﬁned as: “a response to a
medicine which is noxious and unintended, and which occurs at
doses normally used in man.” Additional information was
requested in case of ADR, death, active TB, or treatment
discontinuation. In addition, during adherence counseling, expert
clients asked about side-effects experienced by the patients,
without further precision on the deﬁnition of side-effect.
Data were entered on site weekly using Epi-Data 3.0 software
(The EpiData Association, Odense Denmark), initially by a data
entry clerk and later by the study nurse. Data were analyzed in
Stata 12.1 software (College Station, TX). No imputation was
done in the case of missing variables, apart from the date of death
which was chosen randomly between date of last visit and date of
information about deaths, in the absence of other information.
Mueller et al. Medicine (2017) 96:35 www.md-journal.comMain outcome was described by the proportions that completed
treatment, failed (developed TB), died, defaulted, discontinued,
or transferred. The nonparametric test for trend across ordered
groups was used to assess changes on adherence indicators over
time. In the survival analysis of retention on IPT, death, TB,
default and discontinuation were failures and transfers were
censored. Predeﬁned baseline characteristics that could represent
risk factors for discontinuation (potential confounding factors),
such as clinic, age, sex, ART status, initial baseline CD4 count at
IPT initiation, and occurrence of adverse events, were tested in a
non-parametric survival model, and rates of interruption per
person-years were calculated. Variables associated with retention
on IPT, deﬁned as a log rank test <0.20, were further included in




The study proﬁle has been previously published.[14] Patient
characteristics are detailed in Table 1. Overall 288 patients
initiated IPT for the following reasons: 217 tested positive at the
ﬁrst TST, 47 tested positive at the second repeated TST at 6
months after ﬁrst TST, and 24 had completed TB treatment less
than 6 months ago. Median age was 38 years (interquartile range
[IQR] 31–47). The median time from HIV diagnosis to inclusion
was 2.8 years (IQR: 1.4–4.8), with 252 patients (87.5%) already
on ART. Median CD4 count at inclusion was 477cell/microL
(IQR 344 – 616). A total of 102 (35.9%) had been treated forTable 1




First TST positive 116 (76.3)
Second TST positive 19 (12.5)
Secondary prophylaxis 17 (11.2)
Characteristics at inclusion




On ART, n, % 142 (93.4)
Median duration on ART N=141
in years, IQR 2.1 (0.9–3.6)
Median time since HIV diagnosis N=141
in years, IQR 2.7 (1.4–4.5)
Initial CD4, at HIV diagnosis N=145
Median, IQR 214 (119–312)
CD4 at inclusion N=152
Median, IQR 417 (322–579)
Characteristics at screening visit
Number of females N=105
n pregnant, % 3 (2.9)
Weight, kg N=143
Mean, SD 65.7 (13.2)
TB and IPT history N=148
Past TB treatment 66 (44.6)
Past IPT 6 mo 72 (49.0)
ART = antiretroviral therapy, HIV = human immunodeﬁciency virus, INH = isoniazid, IPT = isoniazid p
3tuberculosis previously, and 109 (38.5%) had previously
received IPT for 6 months.3.2. Outcomes
Out of a total of 288, 286 (99.3%) actually initiated IPT (1
refusal, 1 contraindication not previously recognized) and 253
(87.8%), 234 (81.3%), and 228 (79.2%) were still on IPT after
48, 96, and 144 weeks, respectively (chi2 P= .01, Table 2). Of the
40 patients who did not complete IPT, 21 defaulted (of which 17
also defaulted HIV care), 16 discontinued IPT because of adverse
drug reactions (detailed below), and 2 because of a mistake of the
clinician, who stopped IPT after 6 months instead of 36 months.
Nine patients (3.1%) were transferred to another clinic, and
5 (1.7%) started TB treatment (described in detail below).
Finally, 5 patients (1.7%) died while on IPT, corresponding to a
death rate was 0.7/100 person-years (5 deaths/702 person-years
of follow-up; 95%CI 0.3–1.7%). Of those 5 deaths, there was
1 road trafﬁc accident, 2 deaths of unknown cause, and 2 possibly
due to TB (1 patient with symptoms compatible with TB
meningitis, and 1 with important weight loss); none was
judged possibly or probably related to IPT by the physician in
charge.
Five patients were diagnosed with TB over 702 person-years of
follow-up, corresponding to an annual incidence rate of 0.7/100
person-years (95%CI 0.3–1.7/100PY). Among them, there were
2 new pulmonary drug-sensitive cases, 1 extrapulmonary case
(TB of the spine diagnosed by radiography), and 2 patients
infected with INH-resistant mycobacteria.waziland, 2012–2015.
New Haven Both clinics
N=136 N=288 P
.048
101 (74.3) 217 (75.4)
28 (20.6) 47 (16.3)
7 (5.2) 24 (8.3)
37 (30–46) 38 (31–47) .192
.694
45 (33.1) 92 (31.9)
91 (66.9) 196 (68.1)
110 (80.9) 252 (87.5) .001
N=108 N=249
2.4 (1.1–4.5) 2.2 (1.0–3.8) .052
N=127 N=268
2.8 (1.4–5.0) 2.8 (1.4–4.8) .455
N=130 N=275
245 (133–371) 223 (127–334) .056
N=135 N=287
532 (390–678) 477 (344–616) <.001
N=89 N=196
9 (2.2) 5 (2.6) .770
N=136 N=279
64.6 (11.7) 65.2 (12.5) .466
N=136 N=184
36 (26.5) 102 (35.9) .001
37 (27.2) 109 (38.5) <.001
reventive therapy, IQR = interquartile range, TB = tuberculosis, TST = tuberculin skin test.
Table 2
Cumulative outcomes after 48, 96, and 144 weeks on isoniazid preventive therapy, Swaziland, 2012–2015.
OLOS (N=152) New Haven (N=136) Both clinics (N=288)
W48 W96 W144 W48 W96 W144 W48 W96 W144
Outcome
IPT ongoing/completed 128 (84.2) 118 (77.6) 114 (75.0) 125 (91.9) 116 (85.3) 114 (83.8) 253 (87.8) 234 (81.3) 228 (79.2)
Default
∗
6 (4.0) 9 (5.9) 11 (7.2) 3 (2.2) 9 (6.6) 10 (7.4) 9 (3.2) 17 (5.9) 21 (7.3)
Failure, active TB† 1 (0.7) 2 (1.3) 2 (1.3) 1 (0.7) 3 (2.2) 3 (2.2) 2 (0.7) 5 (1.7) 5 (1.7)
Death 3 (2.0) 3 (2.0) 3 (2.0) 1 (0.7) 1 (0.7) 2 (1.5) 4 (1.4) 4 (1.4) 5 (1.7)
Discontinuation
∗
11 (7.2) 15 (9.9) 16 (10.5) 4 (2.9) 4 (2.9) 4 (2.9) 15 (5.2) 19 (6.6) 20 (6.9)
Transfer out 3 (2.0) 5 (3.2) 6 (4.0) 2 (1.5) 3 (2.2) 3 (2.2) 5 (1.7) 8 (2.8) 9 (3.1)
∗
Including 1 patient who never started IPT.
† One patient treated for TB during the ﬁrst year of follow-up ﬁnally diagnosed with a mycobacteria other than M tuberculosis. Final outcome was classiﬁed as discontinuation.
IPT = isoniazid preventive therapy, TB = tuberculosis.
Mueller et al. Medicine (2017) 96:35 MedicinePatients were followed up for a median of 149 weeks (IQR
146–163 weeks) after IPT start, for a total of 702 person-years
(Fig. 1). In the adjusted non-parametric analysis (Table 3), gender
andART treatmentwere not associatedwith retentionon IPT,while
age, a highCD4count at IPT initiation, absence of adverse event and
clinic were associated with better retention. In a multivariate Cox
model, occurrence of at least 1 adverse event was the strongest
predictor of treatment interruption, whereas increasing age and
higher initial CD4 level were associated with retention under IPT
(P< .001 for goodness-of-ﬁt test). The proportional hazards
assumption was not violated (global test P= .325).
3.3. Tolerance
Adverse drug reactions were mentioned during consultations by
5.6% (15/286), 2.0% (5/253), and 0.9% (1/234) patients during
the ﬁrst, second, and third year of follow-up, respectively. Three
cases of hepatotoxicity were recorded (1.0%), of which 2 were
severe (1 with ALT 5–10x, 1 admitted for jaundice) and 1 mild.
All patients recovered. Other patients mentioned symptoms
which may have been due to hepatotoxicity, such as abdominal
pain (3 patients), or nausea and vomiting (2 patients, including 1
pregnant women). Unfortunately, IPT was often stopped without
liver tests to conﬁrm the diagnosis. The other reported adverse
reactions were 2 cases of rash, 1 of itching, 2 cases of neuropathy,
3 cases of nonspeciﬁc weight loss, 1 psychotic decompensation,
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Figure 1. Kaplan–Meier curve of retention under IPT, by clinic.
4Treatment was discontinued for 16/22 patients reporting
adverse-drug reactions. Of the 16 patients that discontinued
IPT, 1 was found dead at home 2 months after IPT
discontinuation, and 1 pregnancy resulted in stillbirth. The 2
patients with neuropathy recovered only partially. The remain-
ing 13 patients were seen at a later appointment with no
complaints raised.
Side-effects reported to the expert client during the adherence
assessments decreased from 19.0% (16/79) and 50.0% (25/52) at
6 months in OLOS andNewHaven, respectively, to less than 1%
after 30 months. These side-effects were mostly itching,
symptoms of neuropathy (tingling in hands or feet), nonspeciﬁc
pain (joint pains), and other complaints (abdominal pain). None
led to temporary treatment interruptions. Although the nurses
reported few cases of neuropathy (1.4%), up to 4.9% (14/288)
were reported during the interviews with the expert clients.
3.4. Adherence
Adherence was assessed at least once in 252 patients (87.5%),
with a median of 3 assessments per patient (IQR 2–4). Urine was
collected between 1 and 30hours after reported INH intake
(median 13 hours in OLOS and 5 hours in New Haven, ranksum
test P< .001). Not all urine samples were actually tested, mainly
because of the lack of available urine strips or of the staff either
collecting the urine or performing the test. Of all assessments
combined, the proportion of positive urine tests for isoniazid
(INH) was 80.1% (95%CI 76.9–82.9%). Of the 17 patients who
had the urine tested more than 24hours after last INH intake, 14
(82.4%) were still positive. By contrast, out of the 141 negative
urine tests, there were only 11 patients admitting no INH intake
in the past 24hours.
Although objective assessments such as the proportion of
positive urine tests or pill count showed decreasing adherence
over time (test for trend P= .04 and .12, respectively, Table 4),
interview-based adherence indicators, such as the Morisky scale,
or reported days of no intake seemed to improve over time. The
main reason given for missed drug intake was not having the drug
with them, or forgetting to take it.More rarely, patients cited lack
of food, not feeling well, and running out of drugs before the
appointment date.
4. Discussion
To our knowledge, this is the ﬁrst study to document feasibility of
36 months’ IPT in the real life conditions of a high HIV/TB burden
setting. In this setting, patient outcomes were similar or even more
Table 4
Adherence to isoniazid preventive therapy at M6, M12, M18, M24, M30, and M36, by pill count, intake in past 14 days, Morisky scale, and
urine tests, Swaziland, 2012–2015.
M6 M12 M18 M24 M30 M36
N=131 N=121 N=166 N=147 N=84 N=128 Test for trend
n % n % n % n % n % n % P
Urine INH test
Number collected 117 89.3 109 90.1 155 93.4 128 87.1 79 94.0 115 89.8
Positive 96 85.0 87 80.6 124 80.5 104 83.2 58 75.3 81 74.3 .041
Negative 17 15.0 21 19.4 30 19.5 21 16.8 19 24.7 28 25.7
Median pill count, IQR
∗
7 3 to 14 6 0 to 6 8 3 to 15 9 3 to 13 8.5 4 to 17 9 3 to 13 .116
No intake past 24 h 6 4.6 9 7.4 6 3.6 8 5.4 2 2.4 0 0.0 .017
Days of no intake in past
2 weeks, 1 missing
.005
0 days 102 77.9 87 71.9 137 82.5 122 83.0 69 82.1 113 88.3
1 day 15 11.5 21 17.4 17 10.2 12 8.2 7 8.3 5 3.9
2 days 7 5.3 3 2.5 5 3.0 8 5.4 2 2.4 5 3.9
3 days or more 7 5.3 10 8.3 7 4.2 5 3.4 6 7.1 5 3.9
Morisky scale
Do you ever forget to take
your medicine?
26 19.8 13 10.7 13 7.8 15 10.2 8 9.5 5 3.9
Are you careless at times about
taking your medicine?
30 22.9 26 21.5 20 12.0 8 5.4 3 3.6 0 0.0
When feeling better, do you stop
taking your medicine?
1 0.8 2 1.7 0 0.0 0 0.0 0 0.0 0 0.0
If you feel worse, do you stop taking it? 1 0.8 1 0.8 0 0.0 1 0.7 0 0.0 0 0.0
Adherence based on the Morisky scale <.001
Low 1 0.8 2 1.7 0 0.0 0 0.0 0 0.0 0 0.0
Intermediate 41 31.3 31 25.6 28 16.9 21 14.3 8 9.5 5 3.9
High 89 67.9 88 72.7 138 83.1 126 85.7 76 90.5 123 96.1
∗
The number of INH tablets remaining in the INH blister when coming for drug reﬁll, including reﬁll for antiretroviral or other concomitant drug.
INH = isoniazid, IQR = interquartile range.
Table 3
Univariate and multivariate Cox analyses of predictors of isoniazid preventive therapy interruption, Swaziland, 2012–2015.
Univariate Multivariate
n 100 PY Rate 95%CI HR 95%CI P aHR 95%CI P
OLOS clinic 37 345 0.11 0.08–9.15 1
New Haven clinic 22 347 0.06 0.04–0.10 0.61 0.36–1.03 .061
Male 22 223 0.10 0.06–0.15 1
Female 37 465 0.08 0.06–0.11 0.80 0.47–1.36 .424
Not on ART at initiation 10 86 0.12 0.06–0.22 1
On ART at initiation 49 616 0.08 0.06–0.11 0.69 0.35–1.37 .313
Age, per 10 years 0.98 0.96–1.00 .098 0.96 0.93–0.99 .002
Initial CD4 count, per 100 0.85 0.74–0.96 .008 0.84 0.73–0.95 .008
No adverse event 41 663 0.06 0.05 – 0.08 1
Occurrence of at least 1 adverse event 18 39 0.46 0.29 – 0.73 6.4 3.70–11.2 <.001 9.2 5.00–17.10 <.001
aHR = adjusted hazard ratio, ART = antiretroviral therapy, CI = conﬁdence interval, HR = hazard ratio.
Mueller et al. Medicine (2017) 96:35 www.md-journal.comfavorable than results obtained in African clinical trials that
compared 36 months’ isoniazid with other IPT regimens.[8,12] In
particular, the incidence of TB in patients on IPT was comparable
withother studies, even thoughSwazilandcarries ahighTBburden.
However, most patients on IPT were already on ART for some
time, had high CD4 counts, and therefore were at lower risk of TB
than ART-naive patients. Two TB cases were due to isoniazid-
resistant mycobacteria, which is not surprising in a setting were
where 13.2% of new cases and 45.2% of previously treated cases
harbor INH resistance.[20] Interestingly, both age and a high initial
CD4 count favored good retention on IPT, whereas the occurrence
of adverse drug reactions led to treatment interruption.5Occurrence of adverse drug reactions, particularly hepatotox-
icity, was comparable with ﬁndings from the Botswana trial.[21]
By contrast, there were more hepatotoxic events recorded in the
clinical trial in South Africa[12] than found in our study, maybe
related to a higher prevalence of underlying hepatitis B and
alcohol use. Also, liver tests were performed systematically in
clinical trials, in contrast to our setting where, despite existing
recommendations, systematic laboratory testing is rare. In our
study, hepatotoxicity was more frequent during the ﬁrst year on
INH. In these cases, extending IPT from 6 to 36 months did not
much increase the risk of hepatotoxicity. However, we cannot
exclude substantial underreporting of adverse events in our
Mueller et al. Medicine (2017) 96:35 Medicinestudy, considering that almost all adverse events reported led to
treatment discontinuation. This may imply that some side-effects
remained unreported.
Indeed, few cases of neuropathywere reported by the nurses given
the number of reported instances of tingling, burning sensation, or
pain in the hands and feet to the expert clients. Moreover,
management of neuropathy was far from ideal, INH being often
stopped instead of increasing vitamin B6. Training on these aspects
should not be neglected during implementation of INH.
Adherence to INH was good, based on the results of the urine
test, even if it slightly decreasing over time. However, some
selectionbias in adherence estimates is possible, as the patientswho
missed their appointment, and therefore urine testing, may also be
the least adherent. Nonadherent patients were probably also more
likely to have the drug discontinued because of vague side-effects,
whereas the adherent patients were continuing on treatment. Still,
our ﬁndings show that patients can be maintained on INH in
routine conditionswith good adherence. Themain reason given by
patients formissing a dosewas not having the drugwith them.This
suggests that aspects of drugmanagementwhileon travel shouldbe
reinforced during counseling. Also, differences in packaging
between IPT and ART make dispensing a difﬁcult task for health
center staff. Coformulation with cotrimoxazole would certainly
simplify IPT prescription.[22]
In the context of an observational cohort conducted in routine
conditions, our study suffers from some limitations. First, we
cannot exclude some selection in the study population because of
nonexhaustive screeningand/orTST refusal. Second, the studywas
conducted in only 2 clinics, which may not be fully representative
of all the clinics in the country. Also, most patients were already
ART-experienced, and results may not be generalized to contexts
with many ART-naive patients. Third, we did not aim to compare
outcomes of 36months to 6months or non-IPT provision, because
the efﬁcacy of IPT has been established by other studies.[8,12] Also,
the beneﬁts and harms of short- and long-term IPT have been
described previously and therefore were not evaluated.[12,21,22]
Finally, the quality of the information obtained for TB cases or
adverse reactions was limited by the fact that many patients were
not assessed, or onlypartly, bymedical doctors.On the other hand,
1 strength was the limited number of missing data, considering the
simple study set-up.
This feasibility study which was conducted in the public sector
in a resource constrained setting shows that implementation of 36
months’ IPT under routine conditions leads to similar outcomes
as have been demonstrated previously in clinical trials. Indeed,
IPT given for 36 months was well tolerated, with a limited
incidence of TB cases. IPT can easily be integrated into routine
follow-up of HIV-positive patients. Furthermore, adherence can
be maintained in the long run. These ﬁndings support the 2015
updatedWHO recommendation of giving at least 36 months IPT
to adults and adolescents living with HIV, who have an unknown
or positive tuberculin skin test (TST) status, in resource-
constrained settings with high TB incidence and transmission.
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